(Reuters) – U.S. regulators granted Pfizer Inc a reissued patent on its multibillion-dollar Celebrex pain drug that extends its marketing exclusivity until early December 2015, the company said on ...

While this was generally a known event coming down the pipe, Celebrex now has a generic competitor in America. The drug company Actavis PLC (NYSE: ACT) announced on Wednesday that it has launched a ...

Q. I have been using Celebrex for osteoarthritis, and it has worked well for me for many years. The pharmacy substituted generic celecoxib. After only four days, I am in a lot of pain, especially in ...

Pharmaceutical giant Pfizer said on Wednesday it will appeal a US federal court's refusal to extend patent protection for its blockbuster Celebrex drug used to treat arthritis. Pfizer said the US ...

NEW YORK (Reuters) - Pfizer Inc. said on Monday the Federal Court of Appeal of Canada has blocked generic drugmaker Teva Pharmaceutical Industries Ltd. from launching a copycat form of its Celebrex ...

A federal appeals court reversed a Food and Drug Administration ruling that effectively blocked until June Mylan Pharmaceuticals Inc., Watson Laboratories Inc. and Lupin Pharmaceuticals Inc. from ...

Back in 2004, a popular arthritis drug called Vioxx was pulled off the market when studies showed daily long-term use could increase the risk of heart attack, stroke and death. “This was one of the ...

NEW ORLEANS – Pfizer Inc's Celebrex arthritis drug was shown to be at least as safe as the widely used prescription-strength versions of painkillers ibuprofen and naproxen, and does not appear to ...

The US Food and Drug Administration (FDA) today approved the first generic versions of the anti-inflammatory drug celecoxib (Celebrex, Pfizer) in the wake of legal wrangling between the brand-name ...

It is possible for drugs to move cheap generic celebrex across the intestinal wall by diffusion or active transport and be lost in faeces. Some drugs, particularly hormones, can also be excreted into ...

NEW YORK, April 30 (Reuters) - Pfizer Inc. said on Monday the Federal Court of Appeal of Canada has blocked generic drugmaker Teva Pharmaceutical Industries Ltd. from launching a copycat form of its ...